title: [Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3,807 patients].
abstract: BACKGROUND
  Living microorganisms that enter the gut in an active state and exert a positive influence on the host are called probiotics. Numerous experimental and clinical studies were performed recently and confirm both the efficacy and modes of action of probiotic drugs.
  
  
  METHODS
  In a post-marketing-surveillance study with the probiotic Escherichia Coli strain Nissle 1917 (EcN) data on the range of indications as well as on efficacy and tolerance were gathered prospectively in 446 centres. The intended treatment duration was limited to a maximum of 12 weeks.
  
  
  RESULTS
  EcN was used in 3,807 patients with more than 20 different indications, n = 3,511 of whom had gastrointestinal complaints: Among others, 1,067 patients presented with chronically recurring (n = 728) or protracted diarrhoea (n = 339), 415 with inflammatory bowel disease, 679 with irritable bowel syndrome, and 253 with chronic constipation. The overall efficacy was assessed as good to very good by an average of 81.4 % of the therapists. The stool frequency and consistency as well as the symptoms of meteorism and abdominal pain were improved in very many patients. Suspected cases of side effects were documented in only 2.8 % of the patients.
  
  
  CONCLUSIONS
  EcN is frequently used in practice for the treatment of various, mostly gastrointestinal, complaints and is well tolerated.
authors.affiliation: Praxis für Gastroenterologie am Enddarmzentrum Mannheim.
authors.forename: H J
authors.initials: HJ
authors.lastname: Krammer
authors.forename: H
authors.initials: H
authors.lastname: Kämper
authors.forename: R
authors.initials: R
authors.lastname: von Bünau
authors.forename: E
authors.initials: E
authors.lastname: Zieseniss
authors.forename: C
authors.initials: C
authors.lastname: Stange
authors.forename: F
authors.initials: F
authors.lastname: Schlieger
authors.forename: I
authors.initials: I
authors.lastname: Clever
authors.forename: J
authors.initials: J
authors.lastname: Schulze
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D004926:Escherichia coli; D005260:Female; D005767:Gastrointestinal Diseases / Q000453:epidemiology* / Q000382:microbiology / Q000628:therapy*; D005858:Germany / Q000453:epidemiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D019936:Probiotics / Q000627:therapeutic use*; D011446:Prospective Studies; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D016896:Treatment Outcome